https://scholars.lib.ntu.edu.tw/handle/123456789/584580
標題: | Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy | 作者: | Huang C.-N. Huang S.-P. Pao J.-B. Hour T.-C. Chang T.-Y. Lan Y.-H. Lu T.-L. Lee H.-Z. Juang S.-H. Wu P.-P. CHAO-YUAN HUANG Hsieh C.-J. Bao B.-Y. |
關鍵字: | Androgen-deprivation therapy; Oestrogen receptor; Oestrogen response element; Prostate cancer; Single-nucleotide polymorphism | 公開日期: | 2012 | 卷: | 271 | 期: | 5 | 起(迄)頁: | 499-509 | 來源出版物: | Journal of Internal Medicine | 摘要: | Background. Accumulating evidence indicates that oestrogens have significant direct effects on normal prostate development and carcinogenesis. The majority of the biological activities of oestrogens are mediated through the oestrogen receptor (ER), which functions as a hormone-inducible transcription factor to regulate target gene expression by binding to oestrogen response elements (EREs) in the regulatory regions of target genes. Sequence variants in EREs might affect the ER-ERE interaction and subsequent physiological activities. Therefore, we tested whether common single-nucleotide polymorphisms (SNPs) inside EREs are related to the clinical outcomes of androgen-deprivation therapy (ADT) in men with prostate cancer. Methods. We systematically evaluated 49 ERE SNPs predicted using a genome-wide database in a cohort of 601 men with advanced prostate cancer treated with ADT. The prognostic significance of these SNPs on disease progression, prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) after ADT was assessed using Kaplan-Meier analysis and a Cox regression model. Results. Based on multiple hypothesis testing, BNC2 rs16934641 was found to be associated with disease progression; in addition, TACC2 rs3763763 was associated with PCSM, and ALPK1 rs2051778 and TACC2 rs3763763 were associated with ACM. These SNPs remained significant in multivariate analyses that included known clinicopathological predictors. Moreover, a combined genotype effect on ACM was observed when ALPK1 rs2051778 and TACC2 rs3763763 were analysed in combination. Patients with a greater number of unfavourable genotypes had a shorter time to ACM during ADT (P for trend <0.001). Conclusion. The incorporation of ERE SNPs into models with known predictors might improve outcome prediction in patients with prostate cancer receiving ADT. ? 2011 The Association for the Publication of the Journal of Internal Medicine. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84860227006&doi=10.1111%2fj.1365-2796.2011.02449.x&partnerID=40&md5=7be180c13a421347e6f99edf2a57d628 https://scholars.lib.ntu.edu.tw/handle/123456789/584580 |
ISSN: | 0954-6820 | DOI: | 10.1111/j.1365-2796.2011.02449.x | SDG/關鍵字: | antiandrogen; estrogen receptor; gonadorelin agonist; adult; aged; androgen deprivation therapy; article; binding site; estrogen responsive element; genetic polymorphism; genotype; human; major clinical study; male; nucleotide sequence; priority journal; prostate cancer; single nucleotide polymorphism; treatment outcome; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Databases, Genetic; Disease Progression; Estrogens; Gene Expression Regulation; Genome-Wide Association Study; Humans; Kaplan-Meier Estimate; Male; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prostate; Prostatic Neoplasms; Receptors, Estrogen; Transcription Factors; Tumor Suppressor Proteins |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。